Overview

A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
To assess the proposed therapy for patients with advanced gallbladder or biliary cancers.
Phase:
Phase 2
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborator:
Genentech, Inc.
Treatments:
Bevacizumab
Capecitabine
Gemcitabine